Drug news
FDA Panel rejects Humira (AbbVie) for Spondyloarthritis
An advisory panel to the FDA voted against approving Humira ( (adalimumab) from AbbVie, for treating an inflammatory disease of the spine. The panel of independent advisors called for additional trials to prove the efficacy of the drug in treating early-stages of Spondyloarthritis.
The FDA will take the panel's 12 to 1 vote into consideration while deciding upon the final approval for this new use for the drug.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.